We are live on ! Find out more
Handelsbanken Fonder

Handelsbanken Fonder Portfolio holdings

AUM $35.1B
1-Year Est. Return 47.76%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$3.92B
AUM Growth
+$319M
Cap. Flow
+$37.7M
Cap. Flow %
0.96%
Top 10 Hldgs %
26.35%
Holding
186
New
18
Increased
68
Reduced
46
Closed
17

Top Buys

Rank Stock Value
1
ALB icon
Albemarle
ALB
+$26.4M
2
UNH icon
UnitedHealth
UNH
+$26M
3
WSO icon
Watsco Inc
WSO
+$25M
4
PRLB icon
Protolabs
PRLB
+$24.5M
5
BABA icon
Alibaba
BABA
+$22M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.77%
2 Healthcare 14.34%
3 Financials 14.32%
4 Technology 14.29%
5 Communication Services 13.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PX
151
DELISTED
Praxair Inc
PX
$1.88M 0.05%
14,173
+598
+4% +$76.7K
AZRE
152
DELISTED
Azure Power Global Limited
AZRE
$1.76M 0.04%
105,014
+25,431
+32% +$431K
DXCM icon
153
DexCom
DXCM
$33.8B
$1.57M 0.04%
86,000
+46,000
+115% +$850K
VIPS icon
154
Vipshop
VIPS
$7.2B
$1.37M 0.04%
130,000
PRTA icon
155
Prothena Corp
PRTA
$473M
$1.35M 0.03%
25,000
TTM
156
DELISTED
Tata Motors Limited
TTM
$1.32M 0.03%
+40,000
New +$1.4M
ABMD
157
DELISTED
Abiomed Inc
ABMD
$1.15M 0.03%
+8,000
New +$1.08M
SAGE
158
DELISTED
Sage Therapeutics
SAGE
$1.11M 0.03%
14,000
-4,000
-22% -$289K
WB icon
159
Weibo
WB
$1.93B
$931K 0.02%
14,000
ACN icon
160
Accenture
ACN
$110B
$866K 0.02%
+7,000
New +$853K
CHRS icon
161
Coherus Oncology
CHRS
$187M
$789K 0.02%
55,000
+10,000
+22% +$192K
GWRS icon
162
Global Water Resources
GWRS
$219M
$773K 0.02%
+78,110
New +$715K
RXDX
163
DELISTED
Ignyta, Inc.
RXDX
$724K 0.02%
+70,000
New +$568K
HIND
164
Vyome Holdings
HIND
$15.8M
0
HTHT icon
165
Huazhu Hotels Group
HTHT
$12.8B
$484K 0.01%
24,000
FDX icon
166
FedEx
FDX
$76.3B
$435K 0.01%
+2,000
New +$395K
TCOM icon
167
Trip.com Group
TCOM
$29.1B
$431K 0.01%
+8,000
New +$424K
SCHW
168
Charles Schwab
SCHW
$186B
$430K 0.01%
+10,000
New +$400K
CASC
169
DELISTED
Cascadian Therapeutics, Inc.
CASC
$312K 0.01%
84,000
CAH icon
170
Cardinal Health
CAH
$56.3B
-29,875
Closed -$2.44M
CL icon
171
Colgate-Palmolive
CL
$73.6B
-85,000
Closed -$6.22M
ELV icon
172
Elevance Health
ELV
$84.7B
-48,000
Closed -$7.94M
EWZS icon
173
iShares MSCI Brazil Small-Cap ETF
EWZS
$210M
-59,000
Closed -$805K
IAT icon
174
iShares US Regional Banks ETF
IAT
$682M
-10,000
Closed -$448K
INCY icon
175
Incyte
INCY
$24.5B
-6,000
Closed -$802K

Similar funds

Handelsbanken Fonder's Q2 2017 Portfolio in Review

As of Q2 2017, Handelsbanken Fonder held 186 positions worth $3.92B, up 8.9% from $3.6B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Handelsbanken Fonder's Q2 2017 filing shows 18 new, 68 increased, 46 reduced and 17 closed positions. Its largest new stake was Watsco Inc: 175,000 shares worth $27M. The largest sale was Aetna Inc, an estimated $26.1M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Handelsbanken Fonder's largest Q2 2017 buy was Watsco Inc: 175,000 shares worth $27M.
  • Handelsbanken Fonder added most to Albemarle in Q2 2017, an estimated $26.4M increase.
  • Handelsbanken Fonder's biggest Q2 2017 reduction was Aetna Inc, cutting an estimated $26.1M.
  • Handelsbanken Fonder fully exited Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island) in Q2 2017, selling an estimated $23.4M.
  • Handelsbanken Fonder's ten largest holdings make up 26% of its $3.92B portfolio in Q2 2017.
  • Handelsbanken Fonder opened 18 new positions and closed 17 in Q2 2017.
  • Handelsbanken Fonder's portfolio value rose 8.9% quarter-over-quarter to $3.92B.

Based on Handelsbanken Fonder's 13F filing for Q2 2017, filed 7 Jul 2017.